Motus Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Motus Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013387
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Motus Therapeutics Inc (Motus), formerly Rhythm Pharmaceuticals, Inc. is a subsidiary of Rhythm Holding Company LLC, biotechnology company that provides therapies. The company develops peptide therapeutics for the treatment of metabolic diseases. Its products under clinical development include RM-131 and RM-493. Its RM-131 product is derived from the natural ghrelin sequence to treat diabetic gastroparesis and lower GI functional disorders. Motu’s RM-493 product is a peptide agonist, used for the treatment of obesity and diabetes that reduces body fat and insulin resistance. It performs clinical trials in the US. The company also conducts MC4R and Ghrelin programs in peptide engineering, synthesis and formulation. Motus is headquartered in Boston, Massachusetts, the US.

Motus Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Motus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Motus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Motus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Motus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Motus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Motus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Rhythm Pharma Raises Additional USD15 Million in Series A Financing Round 10
Rhythm Holding Raises US$11 Million In Venture Financing 11
Rhythm Pharma Raises US$33 Million In Series B Financing 12
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 14
Rhythm Pharma Raises US$9.5 Million In Venture Financing 15
Motus Therapeutics Secures USD25 Million in Series B Round of Venture Funding 16
Licensing Agreements 17
Rhythm Pharma Enters into Licensing Agreement with Camurus 17
Acquisition 18
Allergan Acquires Motus Therapeutics 18
Motus Therapeutics Inc – Key Competitors 20
Motus Therapeutics Inc – Key Employees 21
Motus Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Corporate Communications 23
Apr 11, 2017: Rhythm Appoints Head of Sanofi Genzyme, Dr. David Meeker, as Chairman of Board of Directors 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Motus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Motus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Motus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Motus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Motus Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Motus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Rhythm Pharma Raises Additional USD15 Million in Series A Financing Round 10
Rhythm Holding Raises US$11 Million In Venture Financing 11
Rhythm Pharma Raises US$33 Million In Series B Financing 12
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 14
Rhythm Pharma Raises US$9.5 Million In Venture Financing 15
Motus Therapeutics Secures USD25 Million in Series B Round of Venture Funding 16
Rhythm Pharma Enters into Licensing Agreement with Camurus 17
Allergan Acquires Motus Therapeutics 18
Motus Therapeutics Inc, Key Competitors 20
Motus Therapeutics Inc, Key Employees 21

★海外企業調査レポート[Motus Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Xodus Group Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Xodus Group Ltd (Xodus) is a provider of engineering and advisory services. The company offers services such as exploration and appraisal, development, projects, asset support, decommissioning and advisory services. Its exploration services comprise regional studies, basin modelling, acreage …
  • Datalogic SpA (DAL):企業の財務・戦略的SWOT分析
    Datalogic SpA (DAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • GFI Informatique:企業の戦略・SWOT・財務分析
    GFI Informatique - Strategy, SWOT and Corporate Finance Report Summary GFI Informatique - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Alon USA Energy Inc (ALJ)-石油・ガス分野:企業M&A・提携分析
    Summary Alon USA Energy Inc (Alon USA), a subsdiary of Delek US Holdings, Inc., is a refiner and marketer of petroleum products. The products offered by the company include various grades of gasoline, diesel fuel, jet fuel, petrochemicals, petrochemical feedstocks, asphalt, and other petroleum-based …
  • Alize Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Alize Pharma SAS (Alize Pharma), a subsidiary of Jazz Pharmaceuticals Plc is a biotechnology company that discovers and develops proteins, biopharmaceutical drugs and peptides. The company provides unacylated ghrelin analog programs that develops stabilized peptide analog of unacylated ghrel …
  • Sysco Corporation:企業の戦略・SWOT・財務情報
    Sysco Corporation - Strategy, SWOT and Corporate Finance Report Summary Sysco Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • US WorldMeds LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary US WorldMeds LLC (US WorldMeds) is a specialty pharmaceutical company that develops, licenses and markets healthcare products to improve lives of patients with challenging conditions and unmet medical needs. The company’s products comprise apokyn, myobloc and revonto. Its apokyn is used for …
  • XL Group Ltd:戦略・SWOT・企業財務分析
    XL Group Ltd - Strategy, SWOT and Corporate Finance Report Summary XL Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Entia Biosciences Inc (ERGO):企業の財務・戦略的SWOT分析
    Summary Entia Biosciences Inc (EBI) is a biotechnology company that provides nutrigenomics solutions for organic health, beauty and agriculture. The company’s solution includes ErgoD2, mushroom dietary supplement, and multi joint support. It offers ErgoD2 solutions such as Ergo-D2-Hemo, Ergo-D2-FLEX …
  • Moderna Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Moderna Therapeutics Inc (Moderna Therapeutics) is a developer of messenger RNA therapeutics. The company provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic v …
  • Akers Biosciences Inc (AKER):製薬・医療:M&Aディール及び事業提携情報
    Summary Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. Its products include BreathScan alcohol detectors, CHUBE, METRO …
  • Electrical Geodesics Inc:企業の製品パイプライン分析2018
    Summary Electrical Geodesics Inc (EGI) is a medical device company that designs, develops and commercializes non-invasive neuro diagnostic products used to monitor and interpret brain activity. The company offers clinical products such as geodesic EEG system 400 series, spike detection software, geo …
  • Daiwa Securities Group Inc:企業の戦略・SWOT・財務分析
    Daiwa Securities Group Inc - Strategy, SWOT and Corporate Finance Report Summary Daiwa Securities Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Interra Resources Ltd (5GI):企業の財務・戦略的SWOT分析
    Summary Interra Resources Ltd (Interra) is an oil and gas company that explores and produces petroleum products. The company’s activities include field development and exploration, and petroleum products production and distribution services. Its production, development and exploration assets compris …
  • Ind-Swift Laboratories Ltd (INDSWFTLAB):企業の財務・戦略的SWOT分析
    Summary Ind-Swift Laboratories Ltd (ISLL) is a manufacturer of active pharmaceutical ingredients and custom chemical products. Its products portfolio includes API’s and finished dosage forms in the therapeutic categories of macrolide antibiotic, antidiabetic, antimigraine, parkinson's disease, antin …
  • Canadian Utilities Ltd (CU):電力:M&Aディール及び事業提携情報
    Summary Canadian Utilities Ltd (CUL), an ATCO company, is an electric utility. The company carries out electricity and natural gas distribution and transmission operations. It constructs and maintains electrical transmission and distribution lines and has stakes in generating plants through subsidia …
  • Mistras Group Inc (MG):企業の財務・戦略的SWOT分析
    Summary Mistras Group Inc (Mistras) is a provider of technology-enabled asset protection solutions that offers used to evaluate the structural integrity of critical energy, industrial and public infrastructure. The company provides products such as acoustic emission, ultrasonic, and vibration and Pd …
  • Axis Bank Limited:企業の戦略・SWOT・財務分析
    Axis Bank Limited - Strategy, SWOT and Corporate Finance Report Summary Axis Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Immunicum AB (IMMU):企業の財務・戦略的SWOT分析
    Summary Immunicum AB (Immunicum) is a biopharmaceutical company that focuses on the development of immuno-oncology therapies for the treatment of solid tumors. The company’s lead development candidate, ilixadencel is in clinical trials for the treatment a range of solid tumors including hepatic cell …
  • Tokyo Electron Ltd (8035):企業の財務・戦略的SWOT分析
    Tokyo Electron Ltd (8035) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆